Medical/Pharmaceuticals
Yidu Tech Achieves Its First Full-Year Profit: FY2026 Net Profit Reaches RMB 78.8 Million, with Positive Operating Cash Flow in the Second Half
BEIJING, July 2, 2026 /PRNewswire/ -- On July 2, Yidu Tech (02158.HK), a leading AI healthcare company, held its annual results presentation to review its financial performance for the fiscal year ended March 31, 2026 ("FY2026"). During the reporting period, the Company achieved its first full-ye...
2026-07-02 17:14
9380
Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery
Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration a...
2026-07-02 10:16
3856
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
SHANGHAI, July 1, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN) to jointly advance the clinical development of a novel I...
2026-07-02 09:00
3209
Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-Class Single-Domain Antibody-Based BBB-Crossing Technology for CNS Diseases
CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, today announced a strategic collaboration with Lonza to develop best-in-class single-domain antibody–base...
2026-07-02 08:05
3170
PharmaResearch Accelerates REJURAN Cosmetics Expansion Across North and South America with Planned Acquisition of CG USA
Acquisition strengthens local manufacturing and logistics capabilities as REJURAN Cosmetics expands across Sephora, Amazon and Canada, with future growth across the Americas in view SEOUL, South Korea, July 1, 2026 /PRNewswire/ -- PharmaResearch, the South Korea-based regenerative medicine comp...
2026-07-01 13:38
4607
ALR Technologies Announces Strategic Acquisition of CGM Medical Technology for US$45 Million & 200M Shares
SINGAPORE, June 30, 2026 /PRNewswire/ -- ALR Technologies SG Ltd ("ALRT" or the "Company") (OTC: ALRTF), the diabetes management company, announces it has entered into a Letter of Intent ("LOI") to acquire 100% equity of CGM Medical Technology Singapore Pte. Ltd. ("CGM Medical Singapore") and ass...
2026-06-30 23:26
8889
Tsingke Biotech Hosts Shanghai Salon on Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeutics
SHANGHAI, June 30, 2026 /PRNewswire/ -- Tsingke Biotech recently hosted the Oligonucleotide Drug Salon at the Hilton Shanghai Zhangjiang, bringing together experts from academia, biopharmaceutical companies, investment firms, and industry service organizations to discuss technological innovation,...
2026-06-30 22:17
3368
Samsung Biologics Releases 2026 ESG Report, Highlighting Progress in Sustainable Operations and Responsible Growth
* Advanced environmental performance through renewable energy transition and enhanced carbon transparency * Strengthened sustainability management and supply chain engagement across the healthcare value chain INCHEON, South Korea, June 30, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.K...
2026-06-30 19:00
2885
METiS TechBio and Boulevard Bio Enter Global License Agreement for Trispecific T-cell Engager
HONG KONG and NEW YORK, June 30, 2026 /PRNewswire/ -- METiS TechBio (7666.HK), a leading AI-driven drug delivery innovation company, today announced it has entered into an exclusive global licensing agreement with Boulevard Bio ("Boulevard"), a U.S. biotechnology company backed by Deerfield Manag...
2026-06-30 17:37
2092
WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapy
WUXI, China, June 30, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi — Drug Substance Facility 2 (MFG2) and Drug Product Facility 1 (DP1) — together ...
2026-06-30 13:49
1963
EirGenix Showcases Dual-Track Biosimilars and CDMO Strategy in U.S. Market Push at BIO 2026
SAN DIEGO, June 30, 2026 /PRNewswire/ -- At BIO 2026, EirGenix presented its comprehensive HER2-positive breast cancer biosimilar portfolio and highlighted its integrated one-stop contract development and manufacturing organization (CDMO) service platform. The company actively pursued U.S. market...
2026-06-30 13:36
2339
Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...
2026-06-30 12:00
2426
Xellar Raises $50 Million Series A Financing to Build the Future of 3D Bio Intelligence
Financing will accelerate the development of human-relevant biological data infrastructure, virtual cell technologies, and next-generation drug discovery BOSTON, June 29, 2026 /PRNewswire/ -- Xellar Biosystems today announced the closing of $50 million in Series A and A+ financing to advance its ...
2026-06-30 10:06
2015
Ever Supreme Launches Phase IIa Clinical Trial for CAR001, Accelerating Global Market Expansion
TAICHUNG, June 29, 2026 /PRNewswire/ -- Ever Supreme Bio Technology Co., Ltd. (TWSE: 6712) announcedon June 28 that CAR001, its proprietarily developed, allogeneic, "off-the-shelf" CAR-T cell therapy for cancer, has successfully cleared review by the Safety Monitoring Committee (SMC). Followin...
2026-06-29 16:47
1707
Harbour BioMed Appoints Dr. Lloyd Klickstein as Scientific Advisor for Immunology
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 28, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today an...
2026-06-29 09:27
2110
Sisram Medical's China Manufacturing Facility Commences Operations as First Locally Produced Alma Rejuve Rolls Off the Line
Localization strategy advances with strengthened end-to-end capabilities across R&D, manufacturing and commercialization HONG KONG, June 28, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group offering Energy-Based Devices (EBD), injectables, and...
2026-06-29 09:00
2939
Key Milestone Achieved: NDA for Sumecigrel Capsule, an Antiplatelet Innovative Drug by Vcare PharmaTech, Officially Accepted
NANJING, China, June 26, 2026 /PRNewswire/ -- Recently, the NDA for Sumecigrel Capsule (formerly known as Vicagrel), a Class 1 innovative antiplatelet drug developed by Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech), has been officially accepted by the NMPA. The drug has now entered the NDA...
2026-06-26 22:30
3976
Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer
Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as a strategy to address therapeut...
2026-06-25 22:51
3643
FIT KING Highlights How Different Consumer Routines Are Shaping At-Home Recovery Needs
The wellness brand outlines how its at-home recovery lineup matches active lifestyles, busy workdays, travel routines, first-time users, and everyday home wellness needs NEW YORK, June 25, 2026 /PRNewswire/ -- As recovery continues to move beyond elite athletics and into everyday wellness, FIT K...
2026-06-25 21:00
3574
CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand
* Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand. * This partnership marks sugemalimab's fifth internati...
2026-06-25 17:44
4259
Week's Top Stories
Most Reposted
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
[Picked up by 309 media titles]
2026-07-30 10:45
J.P. Morgan Private Bank Earns Record 10 Accolades at The Asset Triple A Private Capital Awards 2026
[Picked up by 294 media titles]
2026-07-30 15:00KC Global Media announces new travel series "AXN Ultimate Challenge: Sarawak"
[Picked up by 291 media titles]
2026-07-30 09:12
Articura Launches a New Chapter for Sovereign Healthcare AI in Indonesia
[Picked up by 290 media titles]
2026-07-27 19:02
ADA acquires Algonomy, strengthening its intelligent growth platform for a fully agentic experience
[Picked up by 290 media titles]
2026-07-30 15:30
